Last reviewed · How we verify
AMG334
AMG334, developed by Amgen, is a marketed drug with an undisclosed mechanism of action and primary indication. A key strength is its protected market position, with the key composition patent expiring in 2028. The primary risk is the lack of transparency regarding its specific target, which may limit its differentiation in the market.
At a glance
| Generic name | AMG334 |
|---|---|
| Also known as | Erenumab |
| Sponsor | Amgen |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (PHASE3)
- Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (PHASE3)
- Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients (PHASE3)
- Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study (PHASE4)
- A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine (PHASE4)
- AMG 334 20160172 Pediatric Migraine PK Study. (PHASE1)
- A Controlled Trial of Erenumab in Migraine Prevention (PHASE3)
- Efficacy of Erenumab in Chronic Cluster Headache (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |